Drugmaker Eisai will cut 57 jobs at North Jersey headquarters
Japanese drugmaker Eisai Inc. will lay off 57 employees in Nutley between the end of March and May, public records show, as the pharmaceutical company shaves off 7% of its U.S. workforce. The New ...
FiercePharma4d
Eisai to part ways with 121 employees amid new US restructuring effort
Amid Eisai’s efforts to capitalize on a potential growth surge for its Alzheimer’s disease med Leqembi, the Japanese ...
Eisai, Biogen announce TGA of Australia declined approval of lecanemab
Eisai (ESAIY) and Biogen (BIIB) announced that the Therapeutic Goods Administration, TGA, of Australia has confirmed the initial decision to ...
BioSpace3d
Eisai Will Trim About 7% of US Workforce, Including New Jersey Employees
Eisai’s cuts will affect 121 employees across the Japanese company’s U.S. operations, including 57 people at its American ...
NJBIZ3d
More layoffs coming to NJ’s pharma sector
Along with Nutley-based Eisai, several other New Jersey-based giants in the space have conducted layoffs over the past few ...
pharmaphorum22h
Australia stands firm on 'no' to Alzheimer's drug Leqembi
Eisai and Biogen have been unable to persuade the medicines regulator in Australia to approve their Alzheimer's disease ...
The Pharma Letter20h
SciClone licenses fibroblast growth factor from Eisai
USA/China-based SciClone Pharmaceuticals has entered into a license agreement with Japan’s Eisai for the latter’s fibroblast ...
Fatigue Recovery While You Sleep! Eisai To Launch Designated Quasi-Drug Drink Chocola BB Nightwell
Fatigue Recovery While You Sleep! Eisai to Launch Designated Quasi-Drug Drink Chocola BB Nightwell - Easy-To-Drink Grapefruit Flavor Con ...
Therapeutic Goods Administration decides not to register lecanemab in Australia
BioArctic AB's (publ) (NASDAQ: BIOA B) (STOCKHOLM: BIOA B) partner Eisai announced today that the Therapeutic Goods Administration (TGA) of Australia has declined the approval of lecanemab (generic ...